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Abstract  
Deficiencies of natural anticoagulants protein C, protein S, antithrombin and activated protein C resistance are components 
of inherited thrombophilia. Inherited thrombophilia was defined as a genetically determined tendency towards venous 
thromboembolism, which characteristically occurs in young patients (before 40 to 45 years old), without apparent causes, and tend to 
recur. There have been many debates about the implication of these defects in arterial thromboses (peripheral artery disease, 
myocardial infarction, cerebral infarction) in the recent years. The screening for thrombophilia is recommended for young patients 
with spontaneous thromboses, arterial infarctions, family history of thromboses, personal history of recurrent abortions, with 
thrombosis of venous dural sinuses or strokes or myocardial infarctions, in patients with venous thrombosis in unusual sites, 
because the diagnosis of such a disease leads to a treatment that is lifesaving [1,2]. 
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Introduction 
Hereditary thrombophilia is defined as an 
enhanced inherited tendency to form intravascular 
thrombi, which may be arterial or venous. They 
characteristically occur in young age (before 45 years old) 
and tend to recur. The antithrombin deficiency was 
described in 1965, and then, in the early 1980s, protein C 
and protein S deficiencies were set as causes of inherited 
thrombophilia. In 1993, the activated protein C resistance 
was discovered; the protease generated by the 
thrombomodulin-PC anticoagulant pathway to inactivate 
activated factors V and VIII. Activated protein C 
resistance (APC) is associated in 90% of the cases with a 
point mutation in the factor V gene (factor V Leiden), that 
causes a hypercoagulable state by slowing the 
inactivation of activated factor V by APC. It is the most 
frequent cause of inherited thrombophilia, accounting for 
30% to 50% of the cases [3]. These defects are 
acknowledged as the most important thrombophilic 
conditions for venous thromboembolism. Their prevalence 
in general population vary: 0,2%-0,4% for protein C 
deficiency, 0,2% for protein S deficiency, 0,02% for 
antithrombin deficiency and 4%-5%  for factor V Leiden, 
1:5.000 persons being homozygous for factor V Leiden 
[3]. It is to be established if these defects are involved in 
arterial thromboembolism. Data regarding such an 
association are available mostly from case-reports and 
some studies. The present article is a review of these 
articles. 
Clinical manifestations 
The clinical manifestations of protein C, S, 
antithrombin deficiencies and mutant factor V causing 
activated protein C resistance are similar (Table 1).  
The most common manifestations caused by 
protein C, S, antithrombin deficiencies and activated 
protein C resistance are deep-vein thrombosis of the 
lower limbs, that account for approximately 90% of all 
venous thrombotic episodes and pulmonary embolism, 
though venous thromboses can occur in other venous 
sites (upper limbs veins, hepatic vein, cerebral veins, 
retinal vein, mesenteric vein), but these are rare (5% of 
venous thrombosis in patients with these defects). 
Chronic sequelae can be extremely debilitating, 
because of the post-thrombotic syndrome that can affect 
up to 20% of the patients [5].  
The relative risks of a first episode of venous 
thrombosis due to these types of inherited thrombophilic 
defects are presented in the following table, as published Journal of Medicine and Life Vol. 3, No.4, October‐December 2010 
  413 
© 2010, Carol Davila University Foundation
in the retrospective study LEIDEN TROMBOPHILIA 
STUDY (LETS) and in the prospective study LITE, that 
included over 20.000 subjects [6,7].
 
 
 
 
 
 
 
 
 
 
 
 
 
*All these features are less evident in patients with activated protein C resistance, who appear to be less severely affected clinically.   
 
Risk factor 
 
Retrospective VTE risk  
(LETS study) 
 
Prospective VTE risk  
(LITE study) 
Factor V Leiden (heterozygote)  8.1  3.7 
Factor V Leiden (homozygote)  80  24 
Prothrombin 20210A  2.8  1.9 
Protein C deficiency*  3.1  3.4 
Protein S deficiency*  0.8  not available  
Antithrombin deficiency*  5.0  not available  
*An accurate determination of risk is difficult because of low prevalence 
 
After a first episode of deep vein thrombosis, 
reccurents can occur in patients with or without known 
thrombophilic conditions, the highest risk being in the first 
6 months. A cumulative incidence of deep vein 
thrombosis up to 25% after 5 years of clinical follow-up is 
frequently quoted [9], though Leiden Thrombophilia Study 
reported a cumulative incidence of 12,4% after 5 years 
[8]. 
More rare sites for venous thromboses, but 
characteristic, are: cerebral vein thrombosis, splanchnic 
veins thrombosis - extrahepatic portal vein thrombosis, 
Budd-Chiari syndrome and mesenteric vein thrombosis, 
upper-extremity deep vein thrombosis  [10].  
Consequently, thrombophilic defects are 
responsible for obstetrical complications: early pregnancy 
loss, late pregnancy loss, pre-eclampsia, intrauterine 
growth restriction, and abruptio placentae [11,12,13]. 
Because numerous cases of patients with a 
personal history of previously venous thrombosis, who 
had arterial thrombosis, have been reported in the recent 
years, there have been a lot of studies to establish 
whether patients with thrombophilia and antecedents of 
venous thromboembolisms have a higher risk of arterial 
thrombosis [14,15]. Such a study included 1081 
consecutive patients (649 F/432 M, age range 16-93) 
registered with venous thromboembolism in MAISTHRO 
database (MAin-ISar-THROmbosis). Thrombophilia 
screening tested the presence of factor V Leiden, 
G20210A prothrombin gene mutation, antiphospholipid 
antibodies, factor VII, protein C, protein S and 
antithrombin activities. From all the patients, 40 (3.7%) 
had a prior myocardial infarction (MI) and 41 (3.8%) had a 
stroke. Only the presence of lupus anticoagulant was 
found statistically significant. The conclusion was that the 
cumulative incidence of arterial thrombotic events is low 
for those with antecedents of venous thrombosis, and, 
inherited thrombophilia does not seem to substantially 
increase the risk of arterial thromboses [16]. Another 
study that included members of protein C, S and 
antithrombin deficient families also proved that subjects 
with previous venous thrombosis had a similar risk for 
arterial thrombosis as those without antecedents of 
venous thrombosis, so there seems to be no association 
between venous thrombosis and the subsequent arterial 
thrombosis [17]. 
Only some studies and case reports have 
discussed the implication of trombophilic defects in 
arterial thrombosis. The results are controversial. In one 
cohort family study, the arterial events were diagnosed in 
8% of the 144 subjects with protein C or S deficiencies 
and 1% from the 94 subjects with antithrombin deficiency 
[18]. In another ample study on carriers of familial 
thrombophilia (the  European Prospective Cohort on 
Thrombophilia [EPCOT] study), overall annual incidences 
of myocardial infarction and/or ischemic stroke after 20 
years old were 0.15%, 0.18%, and 0.15% in subjects with 
protein S (n=111), protein C, (n=150), and antithrombin 
deficiency (n=92), respectively [19]. A more recent study 
VENOUS THROMBOEMBOLISM (>90% OF CASES) 
  DEEP VEIN THROMBOSIS OF LOWER LIMBS (common) 
  PULMONARY EMBOLISM (common) 
  SUPERFICIAL THROMBOPHLEBITIS 
  MESENTERIC VEIN THROMBOSIS (rare, but characteristic) 
CEREBRAL VEIN THROMBOSIS (rare, but characteristic)  
FAMILY HISTORY OF THROMBOSIS * 
FIRST THROMBOSIS USUALLY IN YOUNG AGE (< 40 YEARS) * 
FREQUENT RECURRENCES * 
NEONATAL PURPURA FULMINANS (homozygous protein C and protein S deficiency) 
Tabel 1. Clinical features of patients with inherited deficiencies of antithrombin, protein C,  
protein S and activated protein C resistance [4] 
Table 2. Thrombophilia: 
relative risks of a first 
venous thrombosis, as 
published by the 
retrospective Leiden 
Thrombophilia Study (LETS) 
and the prospective cohort 
study LITE [8]  
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reported annual incidences of myocardial infarction and/or 
ischemic stroke of 0.32% (protein S), 0.32% (protein C), 
and 0.21% (antithrombin) in deficient subjects and 0.19% 
in non-deficient subjects >20 years old [16]. In a case-
control study, arterial thrombosis was recorded  more 
frequently in 88 cases with protein S, protein C, or 
antithrombin  deficiency (19% arterial thrombosis) 
compared to control subjects with venous 
thromboembolism without these deficiencies (1% arterial 
thrombosis) [20]. 
Another case-control study reported significantly 
lower plasma levels of activated protein  C in young 
patients with myocardial infarction (n=231) compared to 
healthy controls (n=231)[21]. In a Japanese study, 
subjects  with established inherited protein C deficiency 
and either myocardial infarction (n=10) or ischemic stroke 
(n=11) were on average 11 and 7 years younger at the 
onset of the myocardial infarction or  ischemic stroke, 
respectively, than control subjects with myocardial 
infarction (n=42) or ischemic stroke (n=48) with normal 
protein  C levels [22]. The prospective epidemiological 
Atherosclerosis  Risk in Communities (ARIC) study 
reported that plasma protein  C appeared to have a 
protective role against ischemic stroke but not against 
myocardial infarction [23].  
On the other hand, in other case-control studies, 
the prevalence of these deficiencies were similar between 
cases with ischemic stroke [18,24] or myocardial infarction 
[18,25,26] and matched controls, even for young patients 
[25,26]. Moreover, the low levels of plasma protein C and 
antithrombin were not related to coronary heart disease in 
the ARIC study [23]. The lack of association  between 
protein S, protein C, or antithrombin deficiency and risk for 
arterial thromboses in these studies could be explained by 
the low prevalence of these hereditary deficiencies in the 
general population. More  common, but weaker, 
thrombophilic defects (i.e., factor V Leiden,  the 
prothrombin G20210A mutation) were more frequently 
related to myocardial infarction [25,26,27]  and/or overall 
coronary disease (i.e., myocardial infarction or coronary 
stenosis) [27]. In addition,  it could be speculated that 
protein S, protein C, or antithrombin deficiency in these 
studies might have been acquired rather than hereditary, 
taking into consideration that acquired deficiencies are 
more prevalent. The latter have a high prevalence (up to 
4%) in control subjects [24]. 
A retrospective family cohort study published in 
2008 performed a retrospective follow-up study to assess 
the risk  of arterial thrombosis (myocardial infarction, 
ischemic stroke, transient ischemic attack, or peripheral 
artery disease) in a large series of 468 (52% women, 
average age, 46 ± 17 years old) protein S–, protein C–, or 
antithrombin-deficient subjects, relatives of patients with 
venous thrombosis compared with nondeficient  family 
members [17]. Of the 468 subjects, 35 % had protein S 
deficiency, 39 % protein C deficiency and 26% had   
antithrombin deficiency. These subjects were clinically 
followed up for a 12-year period and 11% of the PS 
deficient patients, 11% of the PC deficient patients and 
8% of the antithrombin deficient patients, had arterial 
thrombosis. Utterly, the lifetime risk of arterial thrombosis 
was   2-fold higher in subjects with any deficiency (i.e., 
protein S, protein C, or antithrombin) compared to non-
deficient subjects. The high risk  of arterial thrombosis 
conferred by any deficiency was evident only until   55 
years old, a 5-fold risk increase. For separate 
deficiencies, the risks were 4.6- (95% CI, 1.1 to 18.3), 6.9- 
(95% CI, 2.1 to 22.2), and 1.1- (95% CI, 0.1 to 10.9) fold 
higher in protein S–, protein  C–, and antithrombin-
deficient subjects, respectively,  before 55 years old. 
Subjects with  any of the three deficiencies were on 
average 11 years younger at the onset  of the ATE, 
compared with nondeficient subjects. Interestingly, only 
protein S and protein C deficiencies were related to ATE 
before  55 years old. Antithrombin deficiency was not 
related to a significantly increased risk either before 55 
years old or thereafter. A high risk for arterial thrombosis 
conferred by protein S or protein C but not antithrombin 
deficiency was also reported earlier [28,29]. It could be 
speculated that the higher risk for arterial thrombosis in 
subjects with protein C deficiency could be ascribed to the 
potent cytoprotective effects of the protein C pathway [30]. 
Protein S deficiency, rather than antithrombin deficiency, 
is associated with arterial thrombosis because of the 
synthesis  of protein S by endothelial cells, whereas 
antithrombin is  synthesized by hepatocytes. Endothelial 
injury as a trigger of thrombosis may be enhanced by a 
preexisting defect in protein S synthesis at the site of the 
injury. Some cytoprotective effects have been attributed to 
protein S [31].  
Conclusions  
Thrombophilia is a serious inherited disease, that 
exposes the carrier to life-threatening arterial and venous 
thrombosis. The incidence of thromboses for the deficient 
persons varies, some of them could never display a 
trombosis, and others can have recurrent thromboses. 
This depends on the genotype in each case, the 
coexistence of other genetic defects and the influence of 
environmental risk factors, such as trauma, surgical 
procedures, oral contraceptive use and pregnancy. Faced 
with a case of thrombosis without any known risk factors, 
the screening of thrombophilia must be performed in order 
to proceed to the adequate anticoagulant treatment. 
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